reports
QuickView: Focus on acute pancreatitis
Capstone is investigating a promising new indication for its Apo-E mimetics triglyceride lowering in acute pancreatitis, an orphan indication with high unmet medical need and requiring only small, rapid clinical trials. AEM-28 has demonstrated significant reductions in VLDL and triglycerides in its Phase I/IIa programme and development for follow-on AEM-28-02 is underway. However, new funding will be needed to progress clinical trials.
QuickView: Initial proof-of-concept established
AEM-28 has demonstrated significant reductions in both VLDL and triglycerides in the Phase I/II programme. This reinforces prior lipid biomarker trends observed in healthy volunteers. These data provide initial proof-of-concept for AEM-28, and more broadly for follow-on products within Capstone’s Apo-E mimetic pipeline including AEM-28-02, supporting progression into further trials, although additional funding will be needed. Future development could include an orphan indication, requiring onl...
QuickView: First human lipid biomarker trends
Early data in healthy volunteers have demonstrated trends in favour of AEM-28 on a number of lipid biomarkers, even at low doses. These are the first-in-man data, which hint at potential future efficacy. AEM-28 continues to be investigated in a Phase Ib/IIa trial, with data anticipated by YE14/Q115. These could pave the way for future development in an orphan cardiovascular indication, although additional funds will likely be needed if data are positive.
QuickView: A new class of cardiovascular drug
First clinical data for AEM-28, an Apo-E mimetic, is expected during H214, which could pave the way for continued development in an orphan cardiovascular (CV) indication, although additional funds will likely be needed if data are positive. Preclinical data suggest AEM-28 can lower cholesterol and protect the artery wall; this profile could have utility in broader CV indications, although development is still at an early stage.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.